 The duration of the study was to be up to 65 weeks, which included a 1- to 3-week Screening period, an Induction period, a Maintenance period, and a 70-day follow-up phone call for all subjects that either terminated early from the study or did not rollover into the extension study NCT 00686374, to evaluate the long-term maintenance of clinical response, safety, and tolerability of repeated administration of adalimumab. 